Research on Drug Traceability and Security System in U.S.
FENG Xiao-chan1, YANG Lu-yao1,2, YANG Yue1,2*
1. School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China;
2. International Food and Drug Policy and Law Center, Shenyang 110016, China
OBJECTIVE To explore and analyze the U.S drug traceability and security system. METHODS By researching domestic and foreign literature,this study analyzed the background of the U.S Drug Supply Chain Security Act,the key elements, characteristics and advantages of the drug traceability and security system, as well as problems and challenges. RESULTS Based on the complete information chain, whose core element is the product identifier, the U. S established a responsibility chain among trade parties for information transmission, verification and investigation of suspect product and disposition of illegitimate products. The system also designed a transition period of 10 years. To ensure drug safety, as well as protect and promote public health, FDA provides guidance and assistance to the industry, controls supply chain security through recalls and other measures, and supervises the trade parties. CONCLUSION The U.S drug traceability and security system can make legal products in the supply chain leave a trace during the whole process. With the transfer of drug ownership, the supply chain participants should take corresponding responsibilities. As a supervisor, FDA can take risk control measures according to the responsibility chain and take the blame. The responsibility of the U.S pharmaceutical supply chain is clear, and the participants work together to avoid the circulation of illegal products under the assistance and guidance of the FDA. The U.S drug traceability and security system is worth being referenced and learned in China.
�����, �����, ����. ����ҩƷ��Ϣ���밲ȫ������ϵ�о�[J]. �й�ҩѧ��־, 2019, 54(11): 934-939.
FENG Xiao-chan, YANG Lu-yao, YANG Yue. Research on Drug Traceability and Security System in U.S.. Chinese Pharmaceutical Journal, 2019, 54(11): 934-939.
MACKEY T K, LIANG B A, YORK P, et al. Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Assessment[J]. Am J Tropical Med Hygiene, 2015, 92(6):59-67.
[2]
MACKEY T K, LIANG B A, YORK P, et al. Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Assessment[J]. Am J Tropical Med Hygiene, 2015, 92(6):59-67.
[3]
National Association of Boards of Pharmacy. Wholesale Drug Distribution: Protecting the Integrity of the Nation��s Prescription Drug Supply[EB/OL]. (2019-01-14)[2013-08]. https://nabp. pharmacy/wp-content/uploads/2016/07/wholesale-drug-distribution-protecting-the-integrity-of-the-nations-prescription-drug-supply. pdf.
[4]
Keith Goldberg. Diversion Scheme Faked Origin Of $440M In Drugs, US Says[EB/OL]. (2019-01-15)[2012-12-14]. https://www. law360. com/articles/401661.
[5]
ELIZABETH A. GALLENAGH, LORI F. Hirsch. Title II �C Licensure of Wholesale Distributors and 3PL��s[EB/OL]. (2019-01-14)[2017-11]. https://www. fdli. org/wp-content/uploads/2017/11/DQSA-Hrisch-B. pdf.
[6]
Dirk Rodgers. Does the DSCSA Have A ��Spirit��[EB/OL]. (2019-09-10)[2019-01-15]. https://www. rxtrace. com/2018/09/does-the-dscsa-have-a-spirit. html/.
[7]
Heather Goodman. How DSCSA Changes the Licensing Landscape[EB/OL]. (2018-09-21)[2019-02-06]. www. pharmexec. com/heather-goodman
[8]
TANG W C, WANG Y L, ZHANG X. Research on Drug TracingScheme and Information Architecture in China[J]. Chin Pharm Aff(�й�ҩ��), 2018, 32(7):30-34.
[9]
FDA. Instruction For Completion Of Form FDA 2 3911-DRUG NOTIFICATION[EB/OL]. [2019-01-18]. https://www. fda. gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM513942. pdf
[10]
FDA. Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs Guidance for Industry[EB/OL]. (2018-10)[2019-02-05]. https://www. fda. gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm624205. pdf.
FDA. Product Identifier Requirements Under the Drug Supply Chain Security Act-Compliance Policy[EB/OL]. (2018-09)[2019-01-17]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM565272.pdf.
[13]
FDA, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier[EB/OL]. (2018-09)[2019-01-18]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM586509.pdf.
[14]
FDA. DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Draft Guidance[EB/OL]. (2014-11)[2019-01-18]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM424895.pdf.
[15]
OIG. Drug supply chain Security:Dsipensers received most tracing information[EB/OL]. (2018-03)[2019-01-19]. https://oig.hhs.gov/oei/reports/oei-05-16-00550.pdf.
[16]
Tracelink.Serialization in 2019:Industrypriorties and business outlook[EB/OL]. (2019-01-14)[2019-01-19]. https://www.tracelink.com/insights/serialization-in-2019-industry-priorities-and-business-outlook.
[17]
Brian Daleiden,Is the market now DSCSA ready?[EB/OL]. [2019-01-19]. http://www.worldpharmatoday.com/Articles/is-the-market-now-dscsa-ready.
[18]
Federal Register. Pilot Project Program Under the Drug Supply Chain Security Act; Request for Comments[EB/OL]. (2017-07-20) [2019-01-19]. https://s3.amazonaws.com/public-inspection. federalregister. gov/2017-15203.pdf
[19]
GEYNISMAN D M, WONG Y N. Drug Supply Chain Security Act and Oral Anticancer Medications[J]. JAMA Oncol, 2016, 2(3), 295.